Insight

Emmanuel Antonarakis Highlights HOXB13 Mutation Linked to Prostate Cancer Risk and Hormonal Therapy Sensitivity

Emmanuel S. Antonarakis/med.umn.edu

Jun 23, 2025, 05:22

Emmanuel Antonarakis Highlights HOXB13 Mutation Linked to Prostate Cancer Risk and Hormonal Therapy Sensitivity

Emmanuel Antonarakis, Clark Endowed Professor of Medicine at Masonic Cancer Center, University of Minnesota, shared on X about a recent paper by Mayuko Kanayama et al. published in Nature:

“A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama”

Title: Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant

Authors: Mayuko Kanayama, Emeline Colomba, Yusra Shao, Sarah M. Nielsen, Edward D. Esplin, Changxue Lu, William B. Isaacs, John C. Henegan, Elisabeth I. Heath, Jun Luo, Régine Marlin and Emmanuel S. Antonarakis

Read Full Article.

Emmanuel Antonarakis

More posts featuring Emmanuel Antonarakis on OncoDaily.

cancer cancer risk Changxue Lu Edward D. Esplin Elisabeth I. Heath Emeline Colomba Emmanuel S Antonarakis John C. Henegan Jun Luo Mayuko Kanayama OncoDaily Oncology prostate cancer Régine Marlin Sarah M. Nielsen William B. Isaacs Yusra Shao

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Yüksel Ürün: Science Is Better When It’s Shared

Oliver Bogler: Grant Tips

Marty Makary: FDA Has Published More than 200 Complete Response Letters